Exelixis (EXEL) Tops Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q2 EPS of $0.31, $0.14 better than the analyst estimate of $0.17. Revenue for the quarter came in at $469.8 million versus the consensus estimate of $447.2 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
